Role of Iron Accumulation in Osteoporosis and the Underlying Mechanisms

Abstract

Osteoporosis is prevalent in postmenopausal women. The underlying reason is mainly estrogen deficiency, but recent studies have indicated that osteoporosis is also associated with iron accumulation after menopause. It has been confirmed that some methods of decreasing iron accumulation can improve the abnormal bone metabolism associated with postmenopausal osteoporosis. However, the mechanism of iron accumulation-induced osteoporosis is still unclear. Iron accumulation may inhibit the canonical Wnt/β-catenin pathway via oxidative stress, leading to osteoporosis by decreasing bone formation and increasing bone resorption via the osteoprotegerin (OPG)/receptor activator of nuclear factor kappa-B ligand (RANKL)/receptor activator of nuclear factor kappa-B (RANK) system. In addition to oxidative stress, iron accumulation also has been reported to inhibit either osteoblastogenesis or osteoblastic function as well as to stimulate either osteoclastogenesis or osteoclastic function directly. Furthermore, serum ferritin has been widely used for the prediction of bone status, and nontraumatic measurement of iron content by magnetic resonance imaging may be a promising early indicator of postmenopausal osteoporosis.

Keywords

menopause / osteoblasts / osteoclasts / Wnt/Beta-catenin / hedgehog

References

[1] JohnstonCB, DagarM. Osteoporosis in older adults. Med Clin North Am, 2020, 104(5): 873-884

[2] GaoS, ZhaoY. Quality of life in postmenopausal women with osteoporosis: a systematic review and meta-analysis. Qual Life Res, 2023, 32(6): 1551-1565

[3] FukumotoS, MatsumotoT. Recent advances in the management of osteoporosis. F1000Res, 2017, 6: 625

[4] AkkawiI, ZmerlyH. Osteoporosis: Current Concepts. Joints, 2018, 6(2): 122-127

[5] Kerschan-SchindlK, MikoschP, Obermayer-PietschB, et al.. Current controversies in clinical management of postmenopausal osteoporosis. Exp Clin Endocrinol Diabetes, 2014, 122(8): 437-444

[6] KhoslaS, HofbauerLC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol, 2017, 5(11): 898-907

[7] HernlundE, SvedbomA, IvergardM, et al.. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos, 2013, 8(1): 136

[8] AgarwalS, AlzahraniFA, AhmedA. Hormone Replacement Therapy: Would it be Possible to Replicate a Functional Ovary?. Int J Mol Sci, 2018, 19(10): 3160

[9] MoyerVA. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 2013, 158(1): 47-54

[10] SongS, GuoY, YangY, et al.. Advances in pathogenesis and therapeutic strategies for osteoporosis. Pharmacol Ther, 2022, 237: 108168

[11] WeinbergED. Role of iron in osteoporosis. Pediatr Endocrinol Rev, 2008, 6(Suppl1): 81-85

[12] LiGF, PanYZ, SiroisP, et al.. Iron homeostasis in osteoporosis and its clinical implications. Osteoporos Int, 2012, 23(10): 2403-2408

[13] MeyerE, KurianMA, HayflickSJ. Neurodegeneration with Brain Iron Accumulation: Genetic Diversity and Pathophysiological Mechanisms. Ann Rev Genomics Hum Genet, 2015, 16: 257-279

[14] PirpamerL, HoferE, GesierichB, et al.. Determinants of iron accumulation in the normal aging brain. Neurobiol Aging, 2016, 43: 149-155

[15] WoodJC, CohenAR, PresselSL, et al.. Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. Br J Haematol, 2016, 172(1): 122-130

[16] AllaliS, de MontalembertM, BrousseV, et al.. Management of iron overload in hemoglobinopathies. Transfusion Clin Biolog, 2017, 24(3): 223-226

[17] AngelucciE, CianciulliP, FinelliC, et al.. Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes. Leukemia Res, 2017, 62: 108-115

[18] TaherAT, SalibaAN. Iron overload in thalassemia: different organs at different rates. Hematolgy Am Soc Hematol Educ Program, 2017, 2017(1): 265-271

[19] WiethoffS, HouldenH. Neurodegeneration with brain iron accumulation. Handb Clin Neurol, 2017, 145: 157-166

[20] HsuCC, SenussiNH, FertrinKY, et al.. Iron overload disorders. Hepatol Commun, 2022, 6(8): 1842-1854

[21] KimBJ, AhnSH, BaeSJ, et al.. Iron overload accelerates bone loss in healthy postmenopausal women and middle-aged men: a 3-year retrospective longitudinal study. J Bone Mineral Res, 2012, 27(11): 2279-2290

[22] KimBJ, LeeSH, KohJM, et al.. The association between higher serum ferritin level and lower bone mineral density is prominent in women ≥45 years of age (KNHANES 2008–2010). Osteoporos Int, 2013, 24(10): 2627-2637

[23] CheJ, YangJ, ZhaoB, et al.. The Effect of Abnormal Iron Metabolism on Osteoporosis. Biol Trace Elem Res, 2020, 195(2): 353-365

[24] ZhangLL, JiangXF, AiHZ, et al.. Relationship of iron overload to bone mass density and bone turnover in postmenopausal women with fragility fractures of the hip. Zhonghua Wai Ke Za Zhi (Chinese), 2013, 51(6): 518-521

[25] JianJ, PelleE, HuangX. Iron and menopause: does increased iron affect the health of postmenopausal women?. Antioxid Redox Signal, 2009, 11(12): 2939-2943

[26] HuangX, XuY, PartridgeNC. Dancing with sex hormones, could iron contribute to the gender difference in osteoporosis?. Bone, 2013, 55(2): 458-460

[27] YangQ, JianJ, KatzS, et al.. 17β-Estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site. Endocrinology, 2012, 153(7): 3170-3178

[28] AhnSH, LeeS, KimH, et al.. Higher serum ferritin level and lower femur neck strength in women at the stage of bone loss (≥ 45 years of age): The Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV). Endocr Res, 2016, 41(4): 334-342

[29] ZwartSR, MorganJL, SmithSM. Iron status and its relations with oxidative damage and bone loss during long-duration space flight on the International Space Station. Am J Clin Nutr, 2013, 98(1): 217-223

[30] ZhangW, XuJ, QiuJ, et al.. Novel and rapid osteoporosis model established in zebrafish using high iron stress. Biochem Biophys Res Commun, 2018, 496(2): 654-660

[31] LiY, BaiB, ZhangY. Bone abnormalities in young male rats with iron intervention and possible mechanisms. Chem Biol Interact, 2018, 279: 21-26

[32] WangZ, DuanR, JinY, et al.. Effects of ferric ammonium citrate on iron accumulation, bone turnover and bone density in ovariectomized rat models with osteoporosis. Cell Mol Biol (Noisy-le-grand), 2022, 68(8): 163-166

[33] LiuLL, LiuGW, LiuH, et al.. Iron accumulation deteriorated bone loss in estrogen-deficient rats. J Orthop Surg Res, 2021, 16(1): 525

[34] De DomenicoI, KushnerJP. Reconstitution of normal hepcidin expression in Hfe-deficient mice after liver transplantation: a new role of HFE in Kupffer cells?. Gastroenterology, 2010, 139(1): 25-27

[35] LiuB, LiuC, ZhongW, et al.. Reduced hepcidin level features osteoporosis. Exp Ther Med, 2018, 16(3): 1963-1967

[36] ShenGS, YangQ, JianJL, et al.. Hepcidin1 knockout mice display defects in bone microarchitecture and changes of bone formation markers. Calcif Tissue Int, 2014, 94(6): 632-639

[37] SunL, GuoW, YinC, et al.. Hepcidin deficiency undermines bone load-bearing capacity through inducing iron overload. Gene, 2014, 543(1): 161-165

[38] ZhangJ, ZhaoH, YaoG, et al.. Therapeutic potential of iron chelators on osteoporosis and their cellular mechanisms. Biomed Pharmacother, 2021, 137: 111380

[39] LiuG, MenP, KennerGH, et al.. Age-associated iron accumulation in bone: implications for postmenopausal osteoporosis and a new target for prevention and treatment by chelation. Biometals, 2006, 19(3): 245-251

[40] LiuG, MenP, KennerGH, et al.. Therapeutic effects of an oral chelator targeting skeletal tissue damage in experimental postmenopausal osteoporosis in rats. Hemoglobin, 2008, 32(1–2): 181-190

[41] BellantiF, Del VecchioGC, PuttiMC, et al.. Model-Based Optimisation of Deferoxamine Chelation Therapy. Pharm Res, 2016, 33(2): 498-509

[42] KusumbeAP, RamasamySK, AdamsRH. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature, 2014, 507(7492): 323-328

[43] QuZH, ZhangXL, TangTT, et al.. Promotion of osteogenesis through beta-catenin signaling by desferrioxamine. Biochem Biophys Res Commun, 2008, 370(2): 332-337

[44] ZhangW, LiG, DengR, et al.. New bone formation in a true bone ceramic scaffold loaded with desferrioxamine in the treatment of segmental bone defect: a preliminary study. J Orthop Sci, 2012, 17(3): 289-298

[45] GuoC, YangK, YanY, et al.. SF-deferoxamine, a bone-seeking angiogenic drug, prevents bone loss in estrogen-deficient mice. Bone, 2019, 120: 156-165

[46] BaschantU, RaunerM, BalaianE, et al.. Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors. Haematologica, 2016, 101(12): 1499-1507

[47] ChenB, YanYL, LiuC, et al.. Therapeutic effect of deferoxamine on iron overload-induced inhibition of osteogenesis in a zebrafish model. Calcif Tissue Int, 2014, 94(3): 353-360

[48] PoggiM, SorrentinoF, PuglieseP, et al.. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. Ann Hematol, 2016, 95(5): 757-763

[49] BilginBK, YozgatAK, IsikP, et al.. The effect of deferasirox on endocrine complications in children with thalassemia. Pediatr Hematol Oncol, 2020, 37(6): 455-464

[50] HouJM, XueY, LinQM. Bovine lactoferrin improves bone mass and microstructure in ovariectomized rats via OPG/RANKL/RANK pathway. Acta Pharmacologica Sinica, 2012, 33(10): 1277-1284

[51] Zhang C, Meng T, Dan Z, et al. Minocycline ameliorates osteoporosis induced by ovariectomy (OVX) and iron accumulation via iron chelation, bone metabolism regulation and inhibition of oxidative stress. QJM, 2020, hcaa271

[52] NemethE, TuttleMS, PowelsonJ, et al.. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 2004, 306(5704): 2090-2093

[53] LiGF, XuYJ, HeYF, et al.. Effect of hepcidin on intracellular calcium in human osteoblasts. Mol Cell Biochem, 2012, 366(1–2): 169-174

[54] ZhangH, WangA, ShenG, et al.. Hepcidin-induced reduction in iron content and PGC-1beta expression negatively regulates osteoclast differentiation to play a protective role in postmenopausal osteoporosis. Aging (Albany NY), 2021, 13(8): 11296-11314

[55] JiangY, YanY, WangX, et al.. Hepcidin inhibition on the effect of osteogenesis in zebrafish. Biochem Biophys Res Commun, 2016, 476(1): 1-6

[56] JiangY, ChenB, YanY, et al.. Hepcidin protects against iron overload-induced inhibition of bone formation in zebrafish. Fish Physiol Biochem, 2019, 45(1): 365-374

[57] ZhangJ, ZhengL, WangZ, et al.. Lowering iron level protects against bone loss in focally irradiated and contralateral femurs through distinct mechanisms. Bone, 2019, 120: 50-60

[58] LiY, BaiB, ZhangY. Expression of iron-regulators in the bone tissue of rats with and without iron overload. Biometals, 2018, 31(5): 749-757

[59] LertsuwanK, NammultriputtarK, NanthawuttiphanS, et al.. Ferrous and ferric differentially deteriorate proliferation and differentiation of osteoblast-like UMR-106 cells. Biometals, 2018, 31(5): 873-889

[60] WinterbournCC. Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicol Lett, 1995, 82–83: 969-974

[61] JiaP, XuYJ, ZhangZL, et al.. Ferric ion could facilitate osteoclast differentiation and bone resorption through the production of reactive oxygen species. J Orthop Res, 2012, 30(11): 1843-1852

[62] MaJ, WangA, ZhangH, et al.. Iron overload induced osteocytes apoptosis and led to bone loss in Hepcidin(−/−) mice through increasing sclerostin and RANKL/OPG. Bone, 2022, 164: 116511

[63] LiG, ZhangH, WuJ, et al.. Hepcidin deficiency causes bone loss through interfering with the canonical Wnt/beta-catenin pathway via Forkhead box O3a. J Orthop Translat, 2020, 23: 67-76

[64] TheillLE, BoyleWJ, PenningerJM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol, 2002, 20: 795-823

[65] HäuslerKD, HorwoodNJ, ChumanY, et al.. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. J Bone Miner Res, 2004, 19(11): 1873-1881

[66] ChoSW, HerSJ, SunHJ, et al.. Differential effects of secreted frizzled-related proteins (sFRPs) on osteoblastic differentiation of mouse mesenchymal cells and apoptosis of osteoblasts. Biochem Biophys Res Commun, 2008, 367(2): 399-405

[67] HolmenSL, ZylstraCR, MukherjeeA, et al.. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem, 2005, 280(22): 21162-21168

[68] XuXJ, ShenL, YangYP, et al.. Serum β-Catenin Levels Associated with the Ratio of RANKL/OPG in Patients with Postmenopausal Osteoporosis. Int J Endocrinol, 2013, 2013: 534352

[69] YangQ, JianJ, AbramsonSB, et al.. Inhibitory effects of iron on bone morphogenetic protein 2-induced osteoblastogenesis. J Bone Miner Res, 2011, 26(6): 1188-1196

[70] HeYF, MaY, GaoC, et al.. Iron overload inhibits osteoblast biological activity through oxidative stress. Biol Trace Elem Res, 2013, 152(2): 292-296

[71] DoyardM, ChappardD, LeroyerP, et al.. Decreased Bone Formation Explains Osteoporosis in a Genetic Mouse Model of Hemochromatosiss. PLoS one, 2016, 11(2): e0148292

[72] YuanY, XuF, CaoY, et al.. Iron Accumulation Leads to Bone Loss by Inducing Mesenchymal Stem Cell Apoptosis Through the Activation of Caspase3. Biol Trace Elem Res, 2019, 187(2): 434-441

[73] XuG, LiX, ZhuZ, et al.. Iron Overload Induces Apoptosis and Cytoprotective Autophagy Regulated by ROS Generation in Mc3t3-E1 Cells. Biol Trace Elem Res, 2021, 199(10): 3781-3792

[74] TianQ, WuS, DaiZ, et al.. Iron overload induced death of osteoblasts in vitro: involvement of the mitochondrial apoptotic pathway. PeerJ, 2016, 4: e2611

[75] DoyardM, FatihN, MonnierA, et al.. Iron excess limits HHIPL-2 gene expression and decreases osteoblastic activity in human MG-63 cells. Osteoporos Int, 2012, 23(10): 2435-2445

[76] PeltierL, BendavidC, CaveyT, et al.. Iron excess upregulates SPNS2 mRNA levels but reduces sphingosine-1-phosphate export in human osteoblastic MG-63 cells. Osteoporos Int, 2018, 29(8): 1905-1915

[77] YangJ, DongD, LuoX, et al.. Iron Overload-Induced Osteocyte Apoptosis Stimulates Osteoclast Differentiation Through Increasing Osteocytic RANKL Production In Vitro. Calcif Tissue Int, 2020, 107(5): 499-509

[78] XiaoW, BeibeiF, GuangsiS, et al.. Iron overload increases osteoclastogenesis and aggravates the effects of ovariectomy on bone mass. J Endocrinol, 2015, 226(3): 121-134

[79] TortoraC, Di PaolaA, CreoliM, et al.. Effects of CB2 and TRPV1 Stimulation on Osteoclast Overactivity Induced by Iron in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis, 2022, 28(8): 1244-1253

[80] WuJ, WangA, WangX, et al.. Rapamycin improves bone mass in high-turnover osteoporosis with iron accumulation through positive effects on osteogenesis and angiogenesis. Bone, 2019, 121: 16-28

[81] WangA, ZhangH, LiG, et al.. Deciphering core proteins of osteoporosis with iron accumulation by proteomics in human bone. Front Endocrinol (Lausanne), 2022, 13: 961903

[82] LiZ, LiD, ChenR, et al.. Cell death regulation: A new way for natural products to treat osteoporosis. Pharmacol Res, 2023, 187: 106635

[83] RuQ, LiY, XieW, et al.. Fighting age-related orthopedic diseases: focusing on ferroptosis. Bone Res, 2023, 11(1): 12

[84] GaoZ, ChenZ, XiongZ, et al.. Ferroptosis - A new target of osteoporosis. Exp Gerontol, 2022, 165: 111836

[85] LuoC, XuW, TangX, et al.. Canonical Wnt signaling works downstream of iron overload to prevent ferroptosis from damaging osteoblast differentiation. Free Radic Biol Med, 2022, 188: 337-350

[86] ZhangH, WangA, LiG, et al.. Osteoporotic bone loss from excess iron accumulation is driven by NOX4-triggered ferroptosis in osteoblasts. Free Radic Biol Med, 2023, 198: 123-136

[87] ZacharskiLR, OrnsteinDL, WoloshinS, et al.. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J, 2000, 140(1): 98-104

[88] JiangR, MansonJE, MeigsJB, et al.. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA, 2004, 291(6): 711-717

[89] HoPJ, TayL, LindemanR, et al.. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. Intern Med J, 2011, 41(7): 516-524

[90] ChenL, ZhuZ, PengX, et al.. Hepatic magnetic resonance imaging with T2* mapping of ovariectomized rats: correlation between iron overload and postmenopausal osteoporosis. Eur Radiol, 2014, 24(7): 1715-1724

[91] JinJ, ChenL, ZhuZ, et al.. Magnetic resonance evaluations of correlation of iron overload and osteoporosis in ovariectomized rats. Zhonghua Yi Xue Za Zhi (Chinese), 2015, 95(7): 537-540

[92] EbrahimpourL, AkhlaghpoorS, AzarkayvanA, et al.. Correlation between bone mineral densitometry and liver/heart iron overload evaluated by quantitative T2* MRI. Hematology, 2012, 17(5): 297-301

[93] AllardHM, CalvelliL, WeyhmillerMG, et al.. Vertebral Bone Density Measurements by DXA are Influenced by Hepatic Iron Overload in Patients with Hemoglobinopathies. J Clin Densitom, 2019, 22(3): 329-337